DOCSLIB.ORG

Pediatric Endocrinology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pediatric Endocrinology Index A description , 199 Abnormalities histology , 202 adiponectin , 187–188 ICU , 210–211 and bone loss, skeletal dynamics , 189–190 insulin-induced hypoglycemia , 209 growth hormone , 188 mechanism, glucocorticoid action , 200–201 hypothalamic-pituitary-ovarian axis , 188–189 metyrapone test , 209–210 insulin , 187 neonates , 211 leptin , 187 pathologic process , 202 thyroid hormone , 188 primary ( see Primary adrenal insuf fi ciency) Achondroplasia prognosis, nineteenth century , 199–200 average intelligence , 61 quality of life (see Quality of life, adrenal insuf fi ciency) cartilage growth , 56 regulation, HPA axis , 201 clinical features , 61 secondary and tertiary ( see Secondary and tertiary C-type natriuretic peptide(CNP) , 62 adrenal insuf fi ciency) management , 62 stimulation test mutation , 61–62 cosyntropin , 209 short stature , 57 CRH , 209 Acid-labile subunit (ALS) , 30, 34–35 glucagon , 209 Acromesomelic dysplasia, type maroteaux (AMDM) , 69 therapy ACTH. See Adrenocorticotropic hormone (ACTH) central failure , 213 ACTH dependent , 253, 255, 256 chronic replacement , 211–212 ACTH independent , 249, 253 newer , 213–214 Addison’s disease standard , 213 screening , 575 stress replacement , 212–213 type 1 diabetes , 574 X-linked leukodystrophy , 214 Adolescents. See Contraception Adrenocortical hyperplasias , 250 Adrenal Adrenocorticotropic hormone (ACTH) carcinomas , 256 adrenal insuf fi ciency Cushing syndrome , 249 baseline level, cosyntropin stimulation test , 209 GIPR , 249 changes , 202 hypothalamic–pituitary , 248 CRH , 209 ultrasound , 255 elevation , 208 Adrenal androgens dehydroepiandrosterone (DHEA) , 187 glucocorticoid , 204 Adrenal axis management , 211 cortisol , 592 metyrapone inhibits , 210 diagnosis , 593 primary , 207, 212 disadvantages, hormonal constellation , 592–593 regulation, HPA axis , 201–202 potential mediators , 592–593 secondary , 208, 213 treatment , 593 CRH , 249 Adrenal insuf fi ciency Cushing syndrome , 249 ACTH , 201, 202 elevation , 405 animal systems , 199 hypothalamic–pituitary–adrenal axis , 248 baseline hormone measurements , 208 independent and dependent activation , 249 CRH , 201 pituitary tumors , 254, 256 CT and MRI , 210 stimulation , 406, 412 S. Radovick and M.H. MacGillivray (eds.), Pediatric Endocrinology: A Practical Clinical Guide, 605 Second Edition, Contemporary Endocrinology, DOI 10.1007/978-1-60761-395-4, © Springer Science+Business Media New York 2013 606 Index Adrenoleukodystrophy , 215 Antithyroid medications , 282–283 Adult-onset growth hormone de fi ciency (AOGHD) AOGHD. See Adult-onset growth hormone de fi ciency autoimmune hypophysitis , 145–146 (AOGHD) BMI , 144 APS-1. See Autoimmune polyglandular syndrome bone density , 142 type 1 (APS-1) bone mineral density , 144 APS-2. See Autoimmune polyglandular syndrome clinical trail , 143–144 type 2 (APS-2) craniopharyngioma , 145 ARH. See Autosomal recessive hypercholesterolemia dose titration , 144–145 (ARH) glucagon stimulation test , 144 Arm span insulin hypoglycemia stimulation test , 144 AMDM , 69 mortality , 141 differences , 59–60 risk , 142 LWD , 63 therapy continuing , 141, 142 measurement , 58, 59 AIDS , 206 reference range , 60 Albumin , 292 Aromatase inhibitors , 79–80 ALS. See Acid-labile subunit (ALS) Atherosclerosis Ambiguous genitalia , 229, 234 adulthood , 545 AMDM. See Acromesomelic dysplasia, type maroteaux coronary, cerebral and peripheral arteries, (AMDM) adults , 552 Amenorrhea dyslipidemia and lesions, young adults , 557 DSD , 443 LDL in human , 549 hypothalamic , 445 Autoimmune endocrine disorders obesity , 445 APS-2 , 574–576 OCP , 458 APS-1 and APECED , 572–574 PCOS ( see Polycystic ovary syndrome (PCOS)) autoantibodies , 571, 572 steroidogenic blocks , 444 celiac disease , 571 Turner syndrome patients , 444 hemoglobin A1c , 571 Androgen hypothesis , 570 adrenal, production , 397, 401, 406 IPEX , 576–577 effects , 401 multiple genes , 570–571 estrogen ratios , 398, 402 syndromes , 569–570 hyperandrogenism , 405, 406 type 1 diabetes , 570 premature adrenarche , 405–406 Autoimmune polyendocrinopathy candidiasis and therapy , 411 ectodermal dystrophy (APECED). Androgen excess See Autoimmune polyglandular syndrome children and adults , 229, 231, 232 type 1 (APS-1) and APECED signs, males and females , 225 Autoimmune polyglandular syndrome type 2 (APS-2) treatment , 230 Addison’s disease , 574 virilizing disorders , 236 APS-3 and APS-4 , 574 Anorexia nervosa (AN) patients, type 1 diabetes , 574–575 clinical features , 186 screening , 575 description , 186 trearments , 575–576 DSM-IV criteria , 186 Autoimmune polyglandular syndrome type 1 (APS-1) endocrine dysfunction , 186 and APECED evaluation , 190–191 asplenia , 573 ghrelin and peptide YY , 189 autoantibodies , 574 HPA axis ( see Hypothalamic-pituitary-adrenal (HPA)) autoimmune endocrine disorders , 572–573 management , 191–192 autoreactive T cells , 572 oxytocin , 189 autosomal recessive disorder , 572 prolactin , 189 candidiasis association , 573–574 vasopressin , 189 diagnosis , 574 Anovulation disease associations , 573 chronic disease , 445 patients , 572–573 description , 443–444 treatment , 574 FSH levels , 444 Autoimmune thyroid disease galactorrhea , 445 chronic ( see Chronic autoimmune thyroiditis) gonadotropin de fi ciency , 444–445 Graves’ disease , 279–286 hypothalamic , 445 Autosomal recessive hypercholesterolemia PCOS , 445 (ARH) , 551 Index 607 B Cancer Beta-cell function, type 2 diabetes , 526–528 acute effects 3 b (Beta)-HSD/ D (delta)4,5-isomerase de fi ciency , 228–229 ACTH , 168 11 b (Beta)-hydroxylase de fi ciency , 232 ADG , 168 Birth trauma , 206 brain and spinal cord tumors , 168 Bisphosphonates , 67 cerebral salt wasting (CSW) , 169 Blomstrand chondrodysplasia , 68–69 chemotherapy , 169–170 BMD. See Bone mineral density (BMD) DI ( see Diabetes insipidus (DI)) Body composition, PWS pituitary gland , 168 GHD , 101 SIADH , 168–169 lean body mass , 101–102 description , 167–168 obesity , 101 endocrine disorders , 168 REE , 101 late effects ( see Late effects treatment, cancer) skinfold measurement, infants , 100, 101 skin , 17 strength and agility , 103–104 TN ( see Thyroid neoplasia) Body mass index (BMI) , 144 Cardiac surgery, children , 297–298 Bone health CDC. See Center for Disease Control (CDC) age , 186 Center for Disease Control (CDC) bone mass , 186, 188, 192 combination hormonal contraception , 471 formation , 187 contraceptive use, MEC , 467, 469 loss , 189–190, 192 guidelines resorption , 187 DMPA , 482, 483 younger age , 186 hormonal contraception , 472 Bone mineral density (BMD) thromboembolism , 473 adults , 144 VTE , 473 issue , 483 women, well-controlled disease , 471 signi fi cant loss , 482 MEC indicate , 475 temporary loss , 482 Central DI. See Diabetes insipidus (DI) Bone strength , 177–178 Central hypothyroidism thyroid function , 299 TSH , 290 C Central precocious puberty (CPP) CAH. See Congenital adrenal hyperplasia (CAH) bone age , 407 CAIS. See Complete androgen insensitivity syndrome (CAIS) bone mineral density (BMD) , 408 Calciopenic rickets breast and pubic hair development , 408 description , 363 children , 406 treatment CNS lesions , 406 anticonvulsant therapy , 369 differential diagnosis, gonadotropin dependent calcium de fi ciency , 368 precocious puberty , 401, 406 CKD , 369 GnRH ( see Gonadotropin-releasing hormone guidelines , 367–368 (GnRH)) heal , 367 hypothalamic–pituitary–gonadal axis , 407 knock-knee deformities , 367 identi fi cation , 406 monitoring and therapy complications , 370 “LH predominance” , 407 primary and secondary , 367 MRI , 407 severe hepatobiliary disease , 369 pelvic ultrasonography , 407 vitamin D ( see Vitamin D) progestational agents , 408 Calciotropic hormones , 340 Cerebral salt wasting (CSW) , 168–169 Calcitonin , 341–342 CETP. See Cholesteryl ester transfer protein (CETP) Calcium Challenges, DSD balance, children , 339–340 CAH , 433 calciotropic hormones , 340 differential diagnosis , 433, 434 calcitonin , 341–342 gender assignment , 435 distribution , 340 parents , 435 fetal and early neonatal period , 342 partial androgen insensitivity , 433 hypercalcemia (see Hypercalcemia) sexual hair , 436 hypocalcemia (see Hypocalcemia) surgical procedures , 435 parathyroid , 340–341 46,XX genetic males and female , 433 physiological functions , 339 46,XY infants with micropenis , 434–435 rickets ( see Calciopenic rickets) young women complains , 435 608 Index Chemotherapy, cancer side effects, combined hormonal contraception , bone strength , 177 478–479 childhood cancer , 168 Complete androgen insensitivity syndrome (CAIS) cytotoxic effects , 173, 175 babies , 432 diabetes mellitus , 170 individuals , 436 gastrointestinal side effects , 169 46,XY females , 436 GHD , 170 Congenital adrenal hyperplasia (CAH) glucocorticoids , 169–170 autosomal recessive disorders , 223 heterogeneous tumor type , 169 clinical and hormonal data , 225–227 high-dose steroid therapy , 170 cortisol synthesis , 223, 224 parenteral nutrition , 169 de fi ciency side effects , 169 3 b (Beta)-HSD/ D (delta)4,5-isomerase , Childhood obesity. See Type II diabetes mellitus 228–229 and obesity 11 b (Beta)-Hydroxylase , 232 Childhood-onset growth hormone de fi ciency (COGHD) 21-Hydroxylase , 230–232 AACE guidelines , 141 17-Hydroxylase/17,20-lyase , 229–230 adults ( see Adult-onset growth hormone de fi ciency P450-Oxidoreductase , 232–233 (AOGHD)) description , 223, 225 approved diagnosis, GHD , 139 diagnosis , 433 arginine/GHRH test , 140–141 enzymes and genes , 225 causes, transition patients , 138
Load more

Recommended publications
  • MR Imaging of Kallmann Syndrome, a Genetic Disorder of Neuronal Migration Affecting the Olfactory and Genital Systems
    MR Imaging of Kallmann Syndrome, a Genetic Disorder of Neuronal Migration Affecting the Olfactory and Genital Systems 1 2 2 3 4 Charles L. Truwit, ' A. James Barkovich, Melvin M. Grumbach, and John J. Martini PURPOSE: We report the MR findings in nine patients with clinical and laboratory evidence of Kallmann syndrome (KS), a genetic disorder of olfactory and gonadal development. In patients with KS, cells that normally express luteinizing hormone-releasing hormone fail to migrate from the medial olfactory placode along the terminalis nerves into the forebrain. In addition, failed neuronal migration from the lateral olfactory placode along the olfactory fila to the forebrain results in aplasia or hypoplasia of the olfactory bulbs and tracts. Patients with KS, therefore, suffer both reproductive and olfactory dysfunction. METHODS: Nine patients with KS underwent direct coronal MR of their olfactory regions in order to assess the olfactory sulci, bulbs, and tracts. A lOth patient had MR findings of KS, although the diagnosis is not yet confirmed by laboratory tests. RESULTS: Abnormalities of the olfactory system were identified in all patients. In particular, the anterior portions of the olfactory sulci were uniformly hypoplastic. The olfactory bulbs and tracts appeared hypoplastic or aplastic in all patients in whom the bulb/ tract region was satisfactorily imaged. In two (possibly three) patients, prominent soft tissue in the region of the bulbs suggests radiographic evidence of neurons that have been arrested before migration. CONCLUSIONS: Previous investigators of patients with KS used axial MR images to demonstrate hypoplasia of the olfactory sulci but offered no assessment of the olfactory bulbs.
    [Show full text]
  • HYPOPITUITARISM YOUR QUESTIONS ANSWERED Contents
    PATIENT INFORMATION HYPOPITUITARISM YOUR QUESTIONS ANSWERED Contents What is hypopituitarism? What is hypopituitarism? 1 What causes hypopituitarism? 2 The pituitary gland is a small gland attached to the base of the brain. Hypopituitarism refers to loss of pituitary gland hormone production. The What are the symptoms and signs of hypopituitarism? 4 pituitary gland produces a variety of different hormones: 1. Adrenocorticotropic hormone (ACTH): controls production of How is hypopituitarism diagnosed? 6 the adrenal gland hormones cortisol and dehydroepiandrosterone (DHEA). What tests are necessary? 8 2. Thyroid-stimulating hormone (TSH): controls thyroid hormone production from the thyroid gland. How is hypopituitarism treated? 9 3. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH): LH and FSH together control fertility in both sexes and What are the benefits of hormone treatment(s)? 12 the secretion of sex hormones (estrogen and progesterone from the ovaries in women and testosterone from the testes in men). What are the risks of hormone treatment(s)? 13 4. Growth hormone (GH): required for growth in childhood and has effects on the entire body throughout life. Is life-long treatment necessary and what precautions are necessary? 13 5. Prolactin (PRL): required for breast feeding. How is treatment followed? 14 6. Oxytocin: required during labor and delivery and for lactation and breast feeding. Is fertility possible if I have hypopituitarism? 15 7. Antidiuretic hormone (also known as vasopressin): helps maintain normal water Summary 15 balance. What do I need to do if I have a pituitary hormone deficiency? 16 Glossary inside back cover “Hypo” is Greek for “below normal” or “deficient” Hypopituitarism may involve the loss of one, several or all of the pituitary hormones.
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in A
    Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in a novel member of the chromodomain gene family cause CHARGE syndrome. L.E.L.M. Vissers1, C.M.A. van Ravenswaaij1, R. Admiraal2, J.A. Hurst3, B.B.A. de Vries1, I.M. Janssen1, W.A. van der Vliet1, E.H.L.P.G. Huys1, P.J. de Jong4, B.C.J. Hamel1, E.F.P.M. Schoenmakers1, H.G. Brunner1, A. Geurts van Kessel1, J.A. Veltman1. 1) Dept Human Genetics, UMC Nijmegen, Nijmegen, Netherlands; 2) Dept Otorhinolaryngology, UMC Nijmegen, Nijmegen, Netherlands; 3) Dept Clinical Genetics, The Churchill Hospital, Oxford, United Kingdom; 4) Children's Hospital Oakland Research Institute, BACPAC Resources, Oakland, CA. CHARGE association denotes the non-random occurrence of ocular coloboma, heart defects, choanal atresia, retarded growth and development, genital hypoplasia, ear anomalies and deafness (OMIM #214800). Almost all patients with CHARGE association are sporadic and its cause was unknown. We and others hypothesized that CHARGE association is due to a genomic microdeletion or to a mutation in a gene affecting early embryonic development. In this study array- based comparative genomic hybridization (array CGH) was used to screen patients with CHARGE association for submicroscopic DNA copy number alterations. De novo overlapping microdeletions in 8q12 were identified in two patients on a genome-wide 1 Mb resolution BAC array. A 2.3 Mb region of deletion overlap was defined using a tiling resolution chromosome 8 microarray. Sequence analysis of genes residing within this critical region revealed mutations in the CHD7 gene in 10 of the 17 CHARGE patients without microdeletions, including 7 heterozygous stop-codon mutations.
    [Show full text]
  • Repercussions of Inborn Errors of Immunity on Growth☆ Jornal De Pediatria, Vol
    Jornal de Pediatria ISSN: 0021-7557 ISSN: 1678-4782 Sociedade Brasileira de Pediatria Goudouris, Ekaterini Simões; Segundo, Gesmar Rodrigues Silva; Poli, Cecilia Repercussions of inborn errors of immunity on growth☆ Jornal de Pediatria, vol. 95, no. 1, Suppl., 2019, pp. S49-S58 Sociedade Brasileira de Pediatria DOI: https://doi.org/10.1016/j.jped.2018.11.006 Available in: https://www.redalyc.org/articulo.oa?id=399759353007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative J Pediatr (Rio J). 2019;95(S1):S49---S58 www.jped.com.br REVIEW ARTICLE ଝ Repercussions of inborn errors of immunity on growth a,b,∗ c,d e Ekaterini Simões Goudouris , Gesmar Rodrigues Silva Segundo , Cecilia Poli a Universidade Federal do Rio de Janeiro (UFRJ), Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro, RJ, Brazil b Universidade Federal do Rio de Janeiro (UFRJ), Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Curso de Especializac¸ão em Alergia e Imunologia Clínica, Rio de Janeiro, RJ, Brazil c Universidade Federal de Uberlândia (UFU), Faculdade de Medicina, Departamento de Pediatria, Uberlândia, MG, Brazil d Universidade Federal de Uberlândia (UFU), Hospital das Clínicas, Programa de Residência Médica em Alergia e Imunologia Pediátrica, Uberlândia, MG, Brazil e Universidad del Desarrollo,
    [Show full text]
  • Loss-Of-Function Mutation in the Prokineticin 2 Gene Causes
    Loss-of-function mutation in the prokineticin 2 gene SEE COMMENTARY causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism Nelly Pitteloud*†, Chengkang Zhang‡, Duarte Pignatelli§, Jia-Da Li‡, Taneli Raivio*, Lindsay W. Cole*, Lacey Plummer*, Elka E. Jacobson-Dickman*, Pamela L. Mellon¶, Qun-Yong Zhou‡, and William F. Crowley, Jr.* *Reproductive Endocrine Unit, Department of Medicine and Harvard Reproductive Endocrine Science Centers, Massachusetts General Hospital, Boston, MA 02114; ‡Department of Pharmacology, University of California, Irvine, CA 92697; §Department of Endocrinology, Laboratory of Cellular and Molecular Biology, Institute of Molecular Pathology and Immunology, University of Porto, San Joa˜o Hospital, 4200-465 Porto, Portugal; and ¶Departments of Reproductive Medicine and Neurosciences, University of California at San Diego, La Jolla, CA 92093 Communicated by Patricia K. Donahoe, Massachusetts General Hospital, Boston, MA, August 14, 2007 (received for review May 8, 2007) Gonadotropin-releasing hormone (GnRH) deficiency in the human associated with KS, although no functional data on the mutant presents either as normosmic idiopathic hypogonadotropic hypo- proteins were provided (17). Herein, we demonstrate that homozy- gonadism (nIHH) or with anosmia [Kallmann syndrome (KS)]. To gous loss-of-function mutations in the PROK2 gene cause IHH in date, several loci have been identified to cause these disorders, but mice and humans. only 30% of cases exhibit mutations in known genes. Recently, murine studies have demonstrated a critical role of the prokineticin Results pathway in olfactory bulb morphogenesis and GnRH secretion. Molecular Analysis of PROK2 Gene. A homozygous single base pair Therefore, we hypothesize that mutations in prokineticin 2 deletion in exon 2 of the PROK2 gene (c.[163delA]ϩ [163delA]) (PROK2) underlie some cases of KS in humans and that animals was identified in the proband, in his brother with KS, and in his deficient in Prok2 would be hypogonadotropic.
    [Show full text]
  • Kallmann Syndrome
    Kallmann syndrome Author: DoctorJean-Pierre Hardelin1 Creation date: July 1997 Updates: May 2002 December 2003 February 2005 Scientific editor: Professor Philippe Bouchard 1 Unité de Génétique des Déficits Sensoriels (INSERM U587), Institut Pasteur, 25 rue du Dr Roux, 75724 Paris cedex 15, France. [email protected] Abstract Keywords Disease name and synonyms Excluded diseases Diagnostic criteria / Definition Differential diagnosis Incidence Clinical description Management including treatment Etiology Diagnostic methods Genetic counseling Prenatal diagnosis Unresolved questions and comments References Abstract Kallmann syndrome combines hypogonadotropic hypogonadism due to GnRH deficiency, with anosmia or hyposmia. Magnetic resonance imaging (MRI) shows hypoplasia or aplasia of the olfactory bulbs. The incidence is estimated at 1 case in 10,000 males and 1 case in 50,000 females. The main clinical features consist of the association of micropenis and cryptorchidism in young boys, the absence of spontaneous puberty, a partial or total loss of the sense of smell (anosmia). Other possible signs include mirror movements of the upper limbs (synkinesis), unilateral or bilateral renal aplasia, cleft lip/palate, dental agenesis, arched feet, deafness. Diagnostic methods consist of hormones evaluation (GnRH stimulation test) as well as qualitative and quantitative olfactometric evaluation. Hormonal replacement is used to induce puberty, and later, fertility. Kallmann syndrome is due to an impaired embryonic development of the olfactory system and the GnRH-synthesizing neurons. Sporadic cases have been predominantly reported. Three modes of inheritance have been described in familial forms: X-linked recessive, autosomal dominant, or more rarely autosomal recessive. To date, only two of the genes responsible for this genetically heterogeneous disease have been identified: KAL-1, responsible for the X-linked form and FGFR1, involved in the autosomal dominant form (KAL-2).
    [Show full text]
  • Gonadotropin-Releasing Hormone Agonist Treatment of Girls with Constitutional Short Stature and Normal Pubertal Development
    0021-972X/96/$03.00/0 Vol. 81, No. 9 Journal of Clmcal Endocrinology and Metabolism Printed in U.S.A. Copyright 0 1996 by The Endocrine Society Gonadotropin-Releasing Hormone Agonist Treatment of Girls with Constitutional Short Stature and Normal Pubertal Development JEAN-CLAUDE CAREL, FRlkDliRIQUE HAY, RliGIS COUTANT, DANIlkLE RODRIGUE, AND JEAN-LOUIS CHAUSSAIN Downloaded from https://academic.oup.com/jcem/article/81/9/3318/2651102 by guest on 23 September 2021 INSERM U-342 and Department of Pediatric Endocrinology, University of Paris V, Hbpital Saint Vincent de Paul, Paris, France ABSTRACT interruption of treatment, bone age was 14.9 2 1.3 yr (~13.5 yr in all GnRH agonists have been proposed to improve final height in patients), height was 149.1 k 4 cm, and final height prognosis was patients with constitutional short stature. We treated 31 girls, aged 150.6 2 3.6 cm. Final height prognosis was 1 2 2.3 cm greater than 11.9 i 1 yr (mean t- SD), with short stature, recent pubertal onset and pretreatment height prognosis (P < 0.02) and 1.2 k 2.2 cm below the predicted final height of 155 cm or less with depot triptorelin. During height predicted at the end of the treatment (P < 0.01). No major the 23 2 4 months of treatment, bone age progression was 0.6 ? 0.3 side-effect was observed. Height SD score decreased during treatment bone age yr/yr, and growth velocity declined from 7 k 2 to 4 2 0.8 with GnRH agonist from -2.3 ? 0.9 to -2.7 -C 0.7 SD score (P < cm/yr (P < 0.0001).
    [Show full text]
  • From Isolated GH Deficiency to Multiple Pituitary Hormone
    European Journal of Endocrinology (2009) 161 S75–S83 ISSN 0804-4643 From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum – a KIMS analysis M Klose, B Jonsson1, R Abs2, V Popovic3, M Koltowska-Ha¨ggstro¨m4, B Saller5, U Feldt-Rasmussen and I Kourides6 Department of Medical Endocrinology, Copenhagen University Hospital, PE2131, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark, 1Department of Women’s and Children’s Health, Uppsala University, SE-75185 Uppsala, Sweden, 2Department of Endocrinology, University of Antwerp, Antwerp, Belgium, 3Neuroendocrine Unit, Institute of Endocrinology, University Clinical Center Belgrade, Belgrade, Serbia, 4KIMS Medical Outcomes, Pfizer Endocrine Care, Sollentuna, Sweden, 5Pfizer Endocrine Care Europe, Tadworth, UK and 6Global Endocrine Care, Pfizer Inc., New York, New York 10017, USA (Correspondence should be addressed to M Klose; Email: [email protected]) Abstract Objective: To describe baseline clinical presentation, treatment effects and evolution of isolated GH deficiency (IGHD) to multiple pituitary hormone deficiency (MPHD) in adult-onset (AO) GHD. Design: Observational prospective study. Methods: Baseline characteristics were recorded in 4110 patients with organic AO-GHD, who were GH naı¨ve prior to entry into the Pfizer International Metabolic Database (KIMS; 283 (7%) IGHD, 3827 MPHD). The effect of GH replacement after 2 years was assessed in those with available follow-up data (133 IGHD, 2207 MPHD), and development of new deficiencies in those with available data on concomitant medication (165 IGHD, 3006 MPHD). Results: IGHD and MPHD patients had similar baseline clinical presentation, and both groups responded similarly to 2 years of GH therapy, with favourable changes in lipid profile and improved quality of life.
    [Show full text]
  • Dental-Craniofacial Manifestation and Treatment of Rare Diseases
    International Journal of Oral Science www.nature.com/ijos REVIEW ARTICLE OPEN Dental-craniofacial manifestation and treatment of rare diseases En Luo1, Hanghang Liu1, Qiucheng Zhao1, Bing Shi1 and Qianming Chen1 Rare diseases are usually genetic, chronic and incurable disorders with a relatively low incidence. Developments in the diagnosis and management of rare diseases have been relatively slow due to a lack of sufficient profit motivation and market to attract research by companies. However, due to the attention of government and society as well as economic development, rare diseases have been gradually become an increasing concern. As several dental-craniofacial manifestations are associated with rare diseases, we summarize them in this study to help dentists and oral maxillofacial surgeons provide an early diagnosis and subsequent management for patients with these rare diseases. International Journal of Oral Science (2019) 11:9 ; https://doi.org/10.1038/s41368-018-0041-y INTRODUCTION In this review, we aim to summarize the related manifestations Recently, the National Health and Health Committee of China first and treatment of dental-craniofacial disorders related to rare defined 121 rare diseases in the Chinese population. The list of diseases, thus helping to improve understanding and certainly these rare diseases was established according to prevalence, diagnostic capacity for dentists and oral maxillofacial surgeons. disease burden and social support, medical technology status, and the definition of rare diseases in relevant international institutions. Twenty million people in China were reported to suffer from these DENTAL-CRANIOFACIAL DISORDER-RELATED RARE DISEASES rare diseases. Tooth dysplasia A rare disease is any disease or condition that affects a small Congenital ectodermal dysplasia.
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature
    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
    [Show full text]